Self-reported PPH and treatment received prior to diagnosis with low VWF in subgroup of parous women (n = 74)
PPH . | LoVIC, n (% of all female enrollees) . |
---|---|
Parous female enrollees | 74/120 (61.7) |
No. of successful pregnancies | 181 |
Mean deliveries per parous female enrollee | 2.5 |
Self-reported PPH, n (% parous female enrollees) | 47/74 (63.5) |
First 24 h only | 22 (29.7) |
24 h to 6 wk only | 11 (14.9) |
Both | 14 (18.9) |
Delayed discharge/readmission | 19 (25.7) |
Medical treatment, n (% parous female enrollees) | |
Consultation/oxytocin IV | 40 (54.0) |
Iron therapy | 15 (20.3) |
Antifibrinolytic therapy | 3 (4.1) |
Additional uterotonics | 2 (2.7) |
Examination under anesthesia | 8 (10.8) |
Uterine tamponade | 1 (1.4) |
Treatment with desmopressin | 1 (1.4) |
Treatment with plasma/platelets/factor concentrate | 0 |
Red blood cell transfusion | 7 (9.5) |
ICU admission/surgical intervention | 1 (1.4) |
Lochia, n (% parous female enrollees) | |
Lochia >6 wk | 19 (25.7) |
Changing pads/tampons >2 hourly | 31 (41.9) |
PPH . | LoVIC, n (% of all female enrollees) . |
---|---|
Parous female enrollees | 74/120 (61.7) |
No. of successful pregnancies | 181 |
Mean deliveries per parous female enrollee | 2.5 |
Self-reported PPH, n (% parous female enrollees) | 47/74 (63.5) |
First 24 h only | 22 (29.7) |
24 h to 6 wk only | 11 (14.9) |
Both | 14 (18.9) |
Delayed discharge/readmission | 19 (25.7) |
Medical treatment, n (% parous female enrollees) | |
Consultation/oxytocin IV | 40 (54.0) |
Iron therapy | 15 (20.3) |
Antifibrinolytic therapy | 3 (4.1) |
Additional uterotonics | 2 (2.7) |
Examination under anesthesia | 8 (10.8) |
Uterine tamponade | 1 (1.4) |
Treatment with desmopressin | 1 (1.4) |
Treatment with plasma/platelets/factor concentrate | 0 |
Red blood cell transfusion | 7 (9.5) |
ICU admission/surgical intervention | 1 (1.4) |
Lochia, n (% parous female enrollees) | |
Lochia >6 wk | 19 (25.7) |
Changing pads/tampons >2 hourly | 31 (41.9) |
ICU, intensive care unit.